News

ThermaMEDx today announced a partnership with EyeCare Partners to expand EverTears distribution across the network of the national provider of clinically integrated eye care.

Combined, the companies say they will create the largest eye bank, tissue recovery and ocular research center in the world.

With the support of Harrington Discovery Institute at University Hospitals, an ophthalmic therapeutic dubbed KIO-301, initially developed by Richard Kramer, PhD, at the University of California, Berkeley (UCB), has successfully been granted approval to start a Phase 1b, first-in-human clinical trial.

Zachary Elkin, MD, MPH, of NYU Langone Eye Center, advises how ophthalmologists and parents should be aware of precautions that should be taken with sports involving small balls and urges the use of protective eyewear.

The gift will establish the Philip C. Hessburg, MD – Art Van Elslander Chair in Ophthalmic Research, which will constitute a permanent endowment fund to support the educational research initiatives at Henry Ford Health by the Detroit Institute of Ophthalmology.

Kodiak Sciences Inc. announced that its BEACON Phase 3 study of tarcocimab, its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept in patients with macular edema due to retinal vein occlusion.

In a study, investigators found that no characteristics of inflammatory bowel disease are related to ocular manifestations of the disease.

According to the company, this Phase 1 dose escalations study will evaluate the safety and tolerability of intravitreal injection of IBI324 in subjects with DME.

At the recent ASRS meeting in New York, Aleksandra Rachitskaya, MD, of the Cleveland Clinic Cole Eye Institute, presented End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD.

Matthew Emanuel, MD, of Glaucoma Associates of Texas, discusses some of the current trends in cataract surgery. He notes it is something that everyone deals with as they get older. It also can be an issue for pediatric patients. Emanuel also notes that it is important for physicians to be able to educate their patients on the disease.

Tarsus Pharmaceuticals has enrolled the first patient in a Phase 2a clinical trial studying TP-03 for the treatment of meibomian gland disease in patients diagnosed with Demodex mites.

The project marks the Orbis Flying Eye Hospital's first return to in-person programming since the start of the pandemic.

The annual Mission Cataract program allows staff to extend its mission to people who need assistance due to unfortunate circumstances.

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

A novel regimen may represent an improvement over current methods of handling postsurgical pain in procedures that require corneal epithelial debridement, according to investigators.

Symptoms in the eye may not be substantial in patients with COVID-19.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study.

Two studies conducted in collaboration with Orbis International explore how providing free glasses to children improves their ability to learn in school and that addressing visual impairment in children can alleviate depression and anxiety.

Investigators discuss the evolution of innovative technology for the hearing impaired and how vision can play a role.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Several issues may restimulate the virus in those patients with prior exposure.

The Grail study finds the device can offer positive outcomes for patients.

Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.

Behin Barahimi, MD, discusses some current trends in the treatment of dry eye disease. An oculoplastic, orbital and reconstructive surgeon, she is a member of the faculty at Vanderbilt Eye Institute.

Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray and provided an update on the commercial performance of the spray in the United States. According to the company, its expanded patient access programs include more eligible patients with dry eye disease.

Gareth Lema, MD, PhD, discusses an innovative eye stroke program at Mount Sinai Health System that involves collaboration among ophthalmologists, the stroke service, and emergency department physicians.